Acute Myeloid Leukemia: A Review
Ari Pelcovits1, Rabin Niroula1
1Alpert Medical School of Brown University, Division of Hematology-Oncology, Rhode Island Hospital, Providence, RI.
Abstract:
Acute myeloid leukemia (AML) is a malignancy of the stem cell precursors of the myeloid lineage (red blood cells, platelets, and white blood cells other than B and T cells). Like other malignancies, it is due to genetic variations that lead to neoplastic changes and clonal proliferation. AML remains a rare malignancy, accounting for only 1.2% of all new cancer diagnoses in the United States per year, but it accounts for close to one third of all leukemias diagnosed.* For much of the 20th and early 21st century treatment paradigms were unchanged with survival curves remaining stagnant for many decades. Recent changes in our understanding of the genetic variations in the disease have led to some promising new therapies with hopes for improved outcomes in the future. Below we review the definitions, diagnosis and classification of AML and how this affects the evolving treatment paradigm of AML.
Insights
Acute myeloid leukemia (AML) is a rare cancer affecting blood stem cells. Recent genetic discoveries are driving new treatments to improve patient outcomes.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Acute myeloid leukemia (AML) is a cancer of myeloid stem cells.
- Genetic variations cause neoplastic changes and clonal proliferation in AML.
- AML accounts for a significant portion of leukemia diagnoses but is rare overall.
Purpose of the Study:
- To review the definitions, diagnosis, and classification of AML.
- To discuss how these factors influence the evolving treatment paradigm for AML.
Main Methods:
- Review of existing literature on AML definitions, diagnosis, classification, and treatment.
- Analysis of the impact of recent genetic discoveries on AML therapy.
Main Results:
- Traditional AML treatment paradigms have seen limited progress for decades.
- Advances in understanding AML genetics are leading to promising new therapeutic strategies.
Conclusions:
- A deeper understanding of AML's genetic basis is crucial for developing effective treatments.
- Evolving treatment paradigms offer hope for improved outcomes in AML patients.
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
07:38Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Related Concept Videos
01:15Differentiation of Common Myeloid Progenitor Cells
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
01:27Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...